Mesothelioma Blood Test Could Help Delay Time Between CT Scans

mesothelioma blood test

A mesothelioma blood test could make it possible to stretch the time between CT scans to monitor treatment progress. That is the conclusion from a team of cancer experts in Italy. The researchers compared the results of the SMRP mesothelioma blood test to CT scans and other prognostic indicators in pleural mesothelioma patients.  Doctors typically use a set of criteria called mRECIST to assess how well a particular therapy is working. mRECIST includes measurements from CT scans. But CT scans are expensive, time-consuming, and expose patients to ionizing radiation.  The goal of the new study was to see how closely SMRP levels correlated with mRECIST results. The team says the blood test appears to be accurate enough that it could … Continue reading Mesothelioma Blood Test Could Help Delay Time Between CT Scans »

Mesothelioma Surgical Decisions: New Method May Make Them Easier

mesothelioma surgical decisions

Cancer researchers in India and the UK have come up with a method for making better mesothelioma surgical decisions. The group focused on peritoneal mesothelioma, the second most common form of asbestos cancer. Peritoneal mesothelioma affects the membrane around the abdominal organs. It can spread throughout the abdomen.  Some peritoneal mesothelioma patients get good results with cytoreductive surgery. But success depends on a number of factors such as how far cancer has spread and where mesothelioma tumors are located. The new decision-making tool reminds doctors of five important factors to consider when making mesothelioma surgical decisions for the best outcomes. It is based on the acronym PAUSE. Peritoneal Mesothelioma and the Promise of CRS/HIPEC Malignant mesothelioma is an especially aggressive … Continue reading Mesothelioma Surgical Decisions: New Method May Make Them Easier »

New Treatment for Malignant Mesothelioma Kills Cancer ‘From the Inside Out’

new treatment for malignant mesothelioma

The University of Vermont is about to start a first-in-human trial of a new kind of treatment for malignant mesothelioma.  The new approach involves a drug called RSO-021. The drug works differently from other cancer therapies. It blocks the ability of cancer cells to manage their own waste products. It’s developers say the new treatment for malignant mesothelioma aims to kill cancer cells from the inside out.  The concept for RSO-021 was first developed at the University of Vermont. Scientists at Wake Forest University School of Medicine and the UK biotech company RS Oncology have tested the drug in mice with promising results.  Human trials of RSO-021 will start soon in the UK. US patients will be recruited in 2022.  … Continue reading New Treatment for Malignant Mesothelioma Kills Cancer ‘From the Inside Out’ »

Diagnostic Accuracy of Lung Fluid Tests for Mesothelioma

diagnostic accuracy

Researchers in Germany say the diagnostic accuracy of lung fluid tests for mesothelioma is high enough that they can be routinely used for diagnosis.  Right now, if mesothelioma is suspected, doctors may order a fluid test first. If the fluid test (cytology) is positive, the doctor usually orders a tissue biopsy (histology) to confirm.  But the German team says their study shows that the diagnostic accuracy of cytology is almost as good as histology for mesothelioma – especially when doctors consider the patient’s hyaluronic acid level, too. Scientists from several German institutions analyzed cytology tests from more than 4,500 suspected cases of pleural mesothelioma. They conclude that cytology is accurate enough to be used routinely for diagnosis.  The Importance of … Continue reading Diagnostic Accuracy of Lung Fluid Tests for Mesothelioma »

Aussie Campaign Warns of Mesothelioma Risk for Homeowners

mesothelioma risk for homeowners

An ad campaign launched by Australia’s top asbestos awareness organization has issued a warning about the mesothelioma risk for homeowners doing renovations.  Asbestos is the number one cause of mesothelioma around the world. Australia has a long history with both asbestos and mesothelioma. The country banned asbestos in 2003 but there is still plenty of it around. Thousands of homes and buildings built before 1990 contain asbestos.  There is a mesothelioma risk for homeowners who come in contact with this asbestos. Mesothelioma is an aggressive and deadly cancer that can kill within months of diagnosis.  If people remodel or attempt renovations without having their home checked for asbestos first, the campaign says they are playing “renovation roulette” with their lives.  … Continue reading Aussie Campaign Warns of Mesothelioma Risk for Homeowners »

Drug Reation May Predict Mesothelioma Immunotherapy Results

mesothelioma immunotherapy results

Patients who have more serious reactions to the drug nivolumab tend to have better mesothelioma immunotherapy results than those who have little or no reaction.  That is the finding of a new study from Japan’s Tokushima University.  Researchers studied the cases of 11 patients treated with nivolumab between 2009 and 2021. They found that the patients who got the sickest from the drug had the best mesothelioma immunotherapy results.  The study’s authors say it’s even more reason to find ways to manage immunotherapy side effects. If patients can work through their worst reactions, more of them might survive mesothelioma.  Nivolumab in Mesothelioma Treatment Nivolumab is an immune checkpoint inhibitor sold under the brand name Opdivo. It is a type of … Continue reading Drug Reation May Predict Mesothelioma Immunotherapy Results »

Mesothelioma Clinical Trials: Are Minorities Underrepresented?

mesothelioma clinical trials

The results of a new study from Harvard and Dana Farber Cancer Institute raise the question of whether ethnic minorities are being fairly represented in mesothelioma clinical trials. The study focused on four of the most common types of cancer in the US: breast, prostate, lung, and colorectal cancer.  It looked at demographic data for close to 6,000 people enrolled in precision oncology trials for these cancers. Researchers found that clinical trials tend to favor white and Asian patients over Hispanic and black patients.  The study could have implications for mesothelioma clinical trials of new, tailored treatments.  Precision Oncology and Mesothelioma Clinical Trials Malignant mesothelioma is a challenging cancer to treat. Mesothelioma cells are good at protecting themselves from damaging … Continue reading Mesothelioma Clinical Trials: Are Minorities Underrepresented? »

Follow-Up Care for Mesothelioma: What Happens After Treatment?

follow-up care for mesothelioma

A new UK study on follow-up care for mesothelioma finds that patients need more continuity, timely information, and more input from their caregivers.  The study focused on three National Health Service facilities in the South of England. Two were secondary care hospitals and the third was a tertiary care center. A tertiary care center has special, high-level expertise in mesothelioma care.  Researchers talked to patients, nurses, caregivers, and members of practice groups called clinical commissioning groups. They used the feedback to develop the UK’s first set of best practices for follow-up care for mesothelioma. They now plan to share these best practices with clinicians across the country to improve after-care for all mesothelioma patients.  The Importance of Follow-Up Care for … Continue reading Follow-Up Care for Mesothelioma: What Happens After Treatment? »

The Role of Asbestos in Mesothelioma Development in Nordic Countries

asbestos in mesothelioma development

A new study of pleural mesothelioma in Nordic countries highlights the critical role of asbestos in mesothelioma development.  Asbestos is the primary cause of mesothelioma around the world. There are many statistics on the incidence of mesothelioma in countries that use asbestos. But there is not much information on mesothelioma incidence, mortality, and survival prior to the popularity of asbestos. This makes it difficult to quantify the influence of asbestos in mesothelioma development.  Researchers from the Czech Republic, Germany, Finland and China compiled the new information using the NORDCAN cancer database. The database includes statistics on mesothelioma in Denmark, Finland, Norway, and Sweden dating back as far as the 1940s.  Their analysis, published in BMC Cancer, is a sobering reminder … Continue reading The Role of Asbestos in Mesothelioma Development in Nordic Countries »

Sensitizer Could Improve Radiotherapy for Pleural Mesothelioma

radiotherapy for pleural mesothelioma

A chemical compound that sensitizes cancer cells to radiation could help improve radiotherapy for pleural mesothelioma. Radiotherapy uses ionizing radiation to scramble the DNA of cancer cells. This makes it harder for cells to replicate and form new tumors.  But mesothelioma cells and other hard-to-treat cancers have ways of protecting themselves against radiation-induced DNA damage. The possibility of damaging healthy cells is another limiting factor in radiotherapy for pleural mesothelioma.  Now, a Japanese study of mice shows a new compound called SQAP can enhance the damage to cancer cells from radiation. The researchers are hopeful it could help keep mesothelioma tumors in check. The Challenge of Radiotherapy for Pleural Mesothelioma Malignant pleural mesothelioma is difficult to treat. This aggressive membrane … Continue reading Sensitizer Could Improve Radiotherapy for Pleural Mesothelioma »

Get your free copy of
“Surviving Mesothelioma” Today!